MTOR and neoplasm: ctDNA, which consists of fragmented DNA shed by tumor cells into the bloodstream, reflects the genetic landscape of the tumor and could provide valuable insights into its molecular profile, permitting us, theoretically to also detect specific genetic alterations such as mutations in the von Hippel-Lindau (VHL) gene or alterations in genes associated with the mTOR pathway [46,47].